Accessibility Statement Skip Navigation
  • Resources
  • Data Privacy
  • Contact Us
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • All Multimedia

        • All Multimedia
        • All Photos
        • All Videos
    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Accessories
        • Computer Hardware
        • Computer Networks
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High-Tech Security
        • Internet Technology
        • Nanotechnology
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art, Culture & Design
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Projections or Forecasts
        • Financing Agreements
        • Insurance
        • Joint Ventures
        • Mutual Funds
        • Offerings
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing/marketing agreements
        • New Products & Services
        • Obituary
        • Outsourcing Businesses
        • Overseas Real Estate (Non-US)
        • Personnel Announcements
        • Residential Real Estate
        • Small-Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Accessories
        • Computer Electronics
        • Computer Hardware
        • Computer Networks
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Design Automation
        • Financial Technology
        • Mobile Devices/Apps
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Natural Gas Utilities
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Computer Accessories
        • Computer Networks
        • Mobile Devices/Apps
        • Telecommunications
        • Telecommunications Carriers & Services
        • Telecommunications Equipment
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wine & Spirits
        • Beverages
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art, Culture & Design
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infectious Disease Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental Products & Services
        • European Government
        • Natural Disasters
        • Not-for-Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Children-related news
        • Disabled Persons
        • Diversity, Equity & Inclusion
        • Hispanic-oriented news
        • LGBTQ+
        • Religion
        • Senior Citizens
        • Veterans
        • Women-Related news
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Request a Demo
    • Partnerships
    • Media Inquiries
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring Home
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us


    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • News Releases
      • Send a Release
      • Data Privacy
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • News Releases
      • Send a Release
      • Data Privacy
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • News Releases
      • Send a Release
      • Data Privacy
      • General Inquiries
      • Request a Demo
      • Partnerships
      • Media Inquiries
      • Editorial Bureaus
      • News Releases
      • Send a Release
      • Data Privacy
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • All Multimedia
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Prenetics Announces Second Quarter 2023 Financial Results


      News provided by

      Prenetics

      15 Sep, 2023, 19:10 CST

      Share this article

      Share this article


      HONG KONG, Sept. 15, 2023 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced financial results for the second quarter ended June 30, 2023, along with recent business updates.

      Second Quarter 2023 Financial Highlights

      • Revenue from continuing operations of US$5.7 million
      • Adjusted EBITDA from continuing operations of US$(5.3) million
      • Cash and other short-term assets[1] of US$214.5 million as of June 30, 2023

      First Half 2023 Financial Highlights

      • Revenue from continuing operations of US$11.6 million
      • Adjusted EBITDA from continuing operations of US$(15.1) million

      "We've always maintained that 2023 would be a transformative year for Prenetics, and our recent strides underscore that belief. We've channelled significant investments into areas where we see not just potential, but a clear path to dominance. Our collaboration with Prof. Dennis Lo, particularly in the realm of early cancer detection, stands as a testament to our commitment and vision. Today, our future business strategy is crystallized into three distinct yet interconnected units: prevention, early cancer detection, and targeted therapy. I am both extremely excited and optimistic about the trajectory we're on, and I believe that the best is yet to come for Prenetics." said Danny Yeung, Chief Executive Officer and Co-Founder of Prenetics.

      Recent Highlights

      • Completed transaction with Prof. Dennis Lo for Insighta as a 50/50 Joint Venture for Multi-Cancer Early Detection in July 2023. Prenetics provided US$100m in consideration, with US$80m in cash and US$20m of shares in Prenetics. Initial clinical trial data is promising. A large multi-country overseas clinical trial is set to begin in early 2024.
      • ACT Genomics is expected to launch a 500-gene panel and a 100-gene panel comprehensive genomic profiling "liquid" biopsy test by the fourth quarter of 2023.
      • ACT Genomics product development work continues for a Minimal Residual Disease (MRD) test is expected to be rolled out by Q2 2024.
      • Multiple distribution and partnership deals are being discussed for Southeast Asia and in the Middle East. More details will be shared once available.
      • Significant improvement in operational efficiency and cost optimization, reducing adjusted EBITDA from continuing operations from a loss of US$(9.8) million in the first quarter of 2023 to US$(5.3) million in the current quarter with further reductions expected in the second half of 2023.

      About Prenetics

      Prenetics (NASDAQ:PRE), a leading genomics-driven health sciences company, is revolutionizing prevention, early detection, and treatment. Our prevention arm, CircleDNA, uses whole exome sequencing to offer the world's most comprehensive consumer DNA test. Insighta, our US$200 million joint venture with renowned scientist Prof. Dennis Lo, underscores our unwavering commitment to saving lives through pioneering multi-cancer early detection technologies. Insighta plans to introduce Presight for lung and liver cancers in 2025, and to expand with Presight One for 10+ cancers in 2027. Lastly, ACT Genomics, our treatment unit, is the first Asia-based company to achieve FDA clearance for comprehensive genomic profiling of solid tumors via ACTOnco. Each of Prenetics' units synergistically enhances our global impact on health, truly embodying our commitment to 'enhancing life through science'. To learn more about Prenetics, please visit www.prenetics.com

      Forward-Looking Statements

      This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company's goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. In some cases, forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "target," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: the Company's ability to further develop and grow its business, including new products and services; its ability to execute on its new business strategy in genomics, precision oncology, and specifically, early detection for cancer; the results of case control studies and/or clinical trials; and its ability to identify and execute on M&A opportunities, especially in precision oncology. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the "Risk Factors" section of the Company's most recent registration statement on Form F-1 and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

      Basis of Presentation

      Unaudited Financial Information and Non-IFRS Financial Measures has been provided in the financial statements tables included at the end of this press release. An explanation of these measures is also included below under the heading "Unaudited Financial Information and Non-IFRS Financial Measures."

      Unaudited Financial Information and Non-IFRS Financial Measures

      To supplement Prenetics' consolidated financial statements prepared in accordance with International Financial Reporting Standards ("IFRS"), the Company is providing non-IFRS measures, adjusted EBITDA from continuing operations, adjusted gross profit from continuing operations and adjusted (loss)/profit attributable to equity shareholders of Prenetics. These non-IFRS financial measures are not based on any standardized methodology prescribed by IFRS and are not necessarily comparable to similarly-titled measures presented by other companies. Management believes these non-IFRS financial measures are useful to investors in evaluating the Company's ongoing operating results and trends.

      Management is excluding from some or all of its non-IFRS results (1) Employee equity-settled share-based payment expenses, (2) depreciation and amortization, (3) finance income and exchange gain or loss, net, and (4) certain items that may not be indicative of our business, results of operations, or outlook, including but not limited to non-cash and/ or non-recurring items. These non-IFRS financial measures are limited in value because they exclude certain items that may have a material impact on the reported financial results. Management accounts for this limitation by analyzing results on an IFRS basis as well as a non-IFRS basis and also by providing IFRS measures in the Company's public disclosures.

      In addition, other companies, including companies in the same industry, may not use the same non-IFRS measures or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-IFRS measures as comparative measures. Because of these limitations, the Company's non-IFRS financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with IFRS. Investors are encouraged to review the non-IFRS reconciliations provided in the tables captioned "Reconciliation of loss from operations from continuing operations under IFRS and adjusted EBITDA from continuing operations (Non-IFRS)", "Reconciliation of gross profit from continuing operations under IFRS and adjusted gross profit from continuing operations (Non-IFRS)" and "Reconciliation of (loss)/profit attributable to equity shareholders of Prenetics under IFRS and adjusted (loss)/profit attributable to equity shareholders of Prenetics (Non-IFRS)" set forth at the end of this document.

      PRENETICS GLOBAL LIMITED

      Unaudited consolidated statements of financial position

      (Expressed in United States dollars unless otherwise indicated)








      June 30,


      March 31,


      December 31,


      2023


      2023


      2022


      $


      $


      $

      Assets






      Property, plant and equipment

      10,031,570


      11,809,757


      13,102,546

      Intangible assets

      14,101,566


      14,463,400


      14,785,875

      Goodwill

      33,800,276


      33,800,276


      33,800,276

      Interests in associates

      559,193


      677,339


      788,472

      Deferred tax assets

      7,631


      7,626


      243,449

      Deferred expenses

      7,097,641


      5,119,170


      6,307,834

      Other non-current assets

      741,816


      1,064,194


      1,292,462

      Non-current assets

      66,339,693


      66,941,762


      70,320,914







      Deferred expenses

      8,588,431


      4,547,611


      4,577,255

      Inventories

      3,768,880


      3,420,013


      4,534,072

      Trade receivables

      5,636,969


      5,718,516


      41,691,913

      Deposits, prepayments and other receivables

      5,594,273


      6,488,436


      6,889,114

      Amount due from an associate

      138,781


      181,942


      -

      Financial assets at fair value through profit or loss

      13,593,201


      17,537,608


      17,537,608

      Short-term deposits

      -


      19,872,581


      19,920,160

      Cash and cash equivalents

      177,179,297


      166,335,875


      146,660,195

      Current assets

      214,499,832


      224,102,582


      241,810,317

      Total assets

      280,839,525


      291,044,344


      312,131,231







      Liabilities






      Deferred tax liabilities

      2,694,720


      2,924,369


      3,185,440

      Warrant liabilities

      1,822,139


      2,314,609


      3,574,885

      Lease liabilities

      3,255,461


      3,627,663


      3,763,230

      Other non-current liabilities

      823,082


      830,562


      949,701

      Non-current liabilities

      8,595,402


      9,697,203


      11,473,256







      Trade payables

      4,226,392


      7,505,724


      7,291,133

      Accrued expenses and other current liabilities

      19,349,105


      6,460,445


      15,611,421

      Contract liabilities

      3,703,874


      4,917,268


      5,674,290

      Lease liabilities

      2,779,193


      2,779,426


      2,882,933

      Liabilities for puttable financial instrument[2]

      13,435,228


      17,459,600


      17,138,905

      Tax payable

      8,534,527


      8,692,193


      8,596,433

      Current liabilities

      52,028,319


      47,814,656


      57,195,115

      Total liabilities

      60,623,721


      57,511,859


      68,668,371







      Equity






      Share capital[3]

      15,791


      15,882


      13,698

      Reserves

      215,291,050


      228,232,194


      237,050,429

      Total equity attributable to equity shareholders of the

        Company

      215,306,841


      228,248,076


      237,064,127

      Non-controlling interests

      4,908,963


      5,284,409


      6,398,733

      Total equity

      220,215,804


      233,532,485


      243,462,860

      Total equity and liabilities

      280,839,525


      291,044,344


      312,131,231

      PRENETICS GLOBAL LIMITED

      Unaudited consolidated statements of profit or loss and other comprehensive income

      (Expressed in United States dollars unless otherwise indicated)






      For the six months ended


      June 30,


      June 30,


      2023


      2022


      $


      $




      (Restated)

      Continuing operations




      Revenue

      11,600,319


      8,291,318

      Direct costs

      (6,988,941)


      (5,524,587)

      Gross profit

      4,611,378


      2,766,731

      Other income and other net gain/(losses)

      2,629,405


      (585,463)

      Selling and distribution expenses[4]

      (4,672,953)


      (2,454,979)

      Research and development expenses[4]

      (6,177,592)


      (3,941,463)

      Administrative and other operating expenses[4]

      (23,158,344)


      (36,608,463)

      Loss from operations

      (26,768,106)


      (40,823,637)

      Fair value loss on financial assets at fair value through profit or loss

      (3,944,407)


      (1,659,343)

      Share-based payments on listing[5]

      -


      (89,546,601)

      Fair value loss on preference shares liabilities

      -


      (60,091,353)

      Fair value gain/(loss) on warrant liabilities

      1,752,746


      (1,539,577)

      Share of losses of associates

      (225,284)


      -

      Other finance costs

      (108,358)


      (3,883,002)

      Loss before taxation

      (29,293,409)


      (197,543,513)

      Income tax credit

      268,827


      1,971,231

      Loss from continuing operations

      (29,024,582)


      (195,572,282)

      Discontinued operation




      (Loss)/profit from discontinued operation, net of tax[6]

      (4,156,608)


      18,409,191

      Loss for the period

      (33,181,190)


      (177,163,091)





      Other comprehensive income for the period




      Item that may be reclassified subsequently to profit or loss:




        Exchange difference on translation of:




        - financial statements of subsidiaries outside Hong Kong

      1,157,683


      (4,775,936)

      Total comprehensive income for the period

      (32,023,507)


      (181,939,027)





      Loss attributable to:




      Equity shareholders of Prenetics

      (32,206,003)


      (177,163,044)

      Non-controlling interests

      (975,187)


      (47)


      (33,181,190)


      (177,163,091)





      Total comprehensive income attributable to:




      Equity shareholders of Prenetics

      (30,533,737)


      (181,938,980)

      Non-controlling interests

      (1,489,770)


      (47)


      (32,023,507)


      (181,939,027)





      Loss per share:




      Basic

      (0.20)


      (3.57)

      Diluted

      (0.20)


      (3.57)





      Loss per share - Continuing operations:




      Basic

      (0.18)


      (3.94)

      Diluted

      (0.18)


      (3.94)





      Weighted average number of common shares:




      Basic

      158,656,029


      49,616,648

      Diluted

      158,656,029


      49,616,648

      PRENETICS GLOBAL LIMITED

      Unaudited consolidated statements of profit or loss and other comprehensive income

      (Expressed in United States dollars unless otherwise indicated)








      For the three months ended


      June 30,


      March 31,


      June 30,


      2023


      2023


      2022


      $


      $


      $




      (Restated)


      (Restated)

      Continuing operations






      Revenue

      5,695,579


      5,904,740


      4,183,499

      Direct costs

      (3,559,119)


      (3,429,822)


      (2,822,908)

      Gross profit

      2,136,460


      2,474,918


      1,360,591

      Other income and other net gain/(losses)

      1,406,281


      1,223,124


      (556,361)

      Selling and distribution expenses[4]

      (2,171,640)


      (2,501,313)


      (1,132,136)

      Research and development expenses[4]

      (2,703,038)


      (3,474,554)


      (2,192,768)

      Administrative and other operating expenses[4]

      (10,834,043)


      (12,324,301)


      (20,267,592)

      Loss from operations

      (12,165,980)


      (14,602,126)


      (22,788,266)

      Fair value loss on financial assets at fair value through

        profit or loss

      (3,944,407)


      -


      (1,659,343)

      Share-based payments on listing[5]

      -


      -


      (89,546,601)

      Fair value loss on preference shares liabilities

      -


      -


      (31,815,352)

      Fair value gain/(loss) on warrant liabilities

      492,470


      1,260,276


      (1,539,577)

      Share of losses of associates

      (112,533)


      (112,751)


      -

      Other finance costs

      (51,464)


      (56,894)


      (1,420,446)

      Loss before taxation

      (15,781,914)


      (13,511,495)


      (148,769,585)

      Income tax credit/(expense)

      245,877


      22,950


      (246,859)

      Loss from continuing operations

      (15,536,037)


      (13,488,545)


      (149,016,444)

      Discontinued operation






      (Loss)/profit from discontinued operation, net of tax[6]

      (6,671,413)


      2,514,805


      4,839,249

      Loss for the period

      (22,207,450)


      (10,973,740)


      (144,177,195)







      Other comprehensive income for the period






      Item that may be reclassified subsequently to profit or loss:






        Exchange difference on translation of:






        - financial statements of subsidiaries and

          associates outside Hong Kong

      1,794,185


      (636,502)


      (4,245,198)

      Total comprehensive income for the period

      (20,413,265)


      (11,610,242)


      (148,422,393)







      Loss attributable to:






      Equity shareholders of Prenetics

      (21,807,573)


      (10,398,430)


      (144,177,194)

      Non-controlling interests

      (399,877)


      (575,310)


      (1)


      (22,207,450)


      (10,973,740)


      (144,177,195)







      Total comprehensive income attributable to:






      Equity shareholders of Prenetics

      (20,037,819)


      (10,495,918)


      (148,422,392)

      Non-controlling interests

      (375,446)


      (1,114,324)


      (1)


      (20,413,265)


      (11,610,242)


      (148,422,393)







      Loss per share:






      Basic

      (0.14)


      (0.07)


      (2.91)

      Diluted

      (0.14)


      (0.07)


      (2.91)







      Loss per share - Continuing operations:






      Basic

      (0.10)


      (0.08)


      (3.00)

      Diluted

      (0.10)


      (0.08)


      (3.00)







      Weighted average number of common shares:






      Basic

      158,963,468


      157,839,309


      49,616,648

      Diluted

      158,963,468


      157,839,309


      49,616,648

      PRENETICS GLOBAL LIMITED

      Unaudited Financial Information and Non-IFRS Financial Measures

      (Expressed in United States dollars unless otherwise indicated)





      Reconciliation of loss from operations from continuing operations under IFRS and adjusted EBITDA from continuing operations (Non-IFRS)






      For the six months ended


      June 30,


      June 30,


      2023


      2022


      $


      $




      (Restated)

      Loss from operations from continuing operations under IFRS

      (26,768,106)


      (40,823,637)

      Employee equity-settled share-based payment expenses

      6,237,845


      17,960,605

      Depreciation and amortization

      3,935,194


      924,050

      Other strategic financing, transactional expense and non-recurring expenses

      4,002,301


      9,202,912

      Finance income, exchange gain or loss, net

      (2,469,946)


      703,368

      Adjusted EBITDA from continuing operations (Non-IFRS)

      (15,062,712)


      (12,032,702)





      Reconciliation of gross profit from continuing operations under IFRS and adjusted gross profit from continuing operations (Non-IFRS)






      For the six months ended


      June 30,


      June 30,


      2023


      2022


      $


      $




      (Restated)

      Gross profit from continuing operations under IFRS

      4,611,378


      2,766,731

      Depreciation and amortization

      719,974


      51,786

      Adjusted gross profit from continuing operations (Non-IFRS)

      5,331,352


      2,818,517





      Reconciliation of loss attributable to equity shareholders of Prenetics under IFRS and adjusted (loss)/profit attributable to equity shareholders of Prenetics (Non-IFRS)






      For the six months ended


      June 30,


      June 30,


      2023


      2022


      $


      $




      (Restated)

      Loss attributable to equity shareholders of Prenetics under IFRS

      (32,206,003)


      (177,163,044)

      Employee equity-settled share-based payment expenses

      6,237,845


      22,344,081

      Other strategic financing, transactional expense and non-recurring expenses

      9,917,705


      10,549,874

      Share-based payment on listing                                                                              

      -


      89,546,601

      Fair value loss on preference shares liabilities

      -


      60,091,353

      Fair value (gain)/loss on warrant liabilities

      (1,752,746)


      1,539,577

      Fair value loss on financial assets at fair value through profit or loss

      3,944,407


      1,659,343

      Adjusted (loss)/profit attributable to equity shareholders of Prenetics

        (Non-IFRS)

      (13,858,792)


      8,567,785

      PRENETICS GLOBAL LIMITED

      Unaudited Financial Information and Non-IFRS Financial Measures

      (Expressed in United States dollars unless otherwise indicated)







      Reconciliation of loss from operations from continuing operations under IFRS and adjusted EBITDA from continuing operations (Non-IFRS)








      For the three months ended


      June 30,


      March 31,


      June 30,


      2023


      2023


      2022


      $


      $


      $




      (Restated)


      (Restated)

      Loss from operations from continuing operations

        under IFRS

      (12,165,980)


      (14,602,126)


      (22,788,266)

      Employee equity-settled share-based payment

        expenses

      3,296,861


      2,940,984


      10,215,945

      Depreciation and amortization

      1,863,626


      2,071,568


      230,422

      Other strategic financing, transactional expense and

        non-recurring expenses

      3,077,902


      924,399


      7,638,653

      Finance income, exchange gain or loss, net

      (1,323,782)


      (1,146,164)


      671,596

      Adjusted EBITDA from continuing operations

        (Non-IFRS)

      (5,251,373)


      (9,811,339)


      (4,031,650)







      Reconciliation of gross profit from continuing operations under IFRS and adjusted gross profit from continuing operations (Non-IFRS)








      For the three months ended


      June 30,


      March 31,


      June 30,


      2023


      2023


      2022


      $


      $


      $




      (Restated)


      (Restated)

      Gross profit from continuing operations under IFRS

      2,136,460


      2,474,918


      1,360,591

      Depreciation and amortization

      335,648


      384,326


      26,729

      Adjusted gross profit from continuing operations

       (Non-IFRS)

      2,472,108


      2,859,244


      1,387,320







      Reconciliation of loss attributable to equity shareholders of Prenetics under IFRS and adjusted (loss)/profit attributable to equity shareholders of Prenetics (Non-IFRS)








      For the three months ended


      June 30,


      March 31,


      June 30,


      2023


      2023


      2022


      $


      $


      $




      (Restated)


      (Restated)

      Loss attributable to equity shareholders of Prenetics

        under IFRS

      (21,807,573)


      (10,398,430)


      (144,177,194)

      Employee equity-settled share-based payment

        expenses

      3,113,656


      3,124,189


      12,966,966

      Other strategic financing, transactional expense and

        non-recurring expenses

      7,678,799


      2,238,906


      8,854,689

      Share-based payment on listing

      -


      -


      89,546,601

      Fair value loss on preference shares liabilities

      -


      -


      31,815,352

      Fair value (gain)/loss on warrant liabilities

      (492,470)


      (1,260,276)


      1,539,577

      Fair value loss on financial assets at fair value through

        profit or loss

      3,944,407


      -


      1,659,343

      Adjusted (loss)/profit attributable to equity

        shareholders of Prenetics (Non-IFRS)

      (7,563,181)


      (6,295,611)


      2,205,334

      [1] Represents current assets, including cash and cash equivalents totaling US$177.2 million, financial assets at fair value through profit or loss of US$13.6 million, and trade receivables of US$5.6 million, amongst other accounting line items under current assets.

      [2] In connection with the acquisition of ACT Genomics, the remaining shareholders of ACT Genomics - representing 25.61% of the fully diluted shareholding of ACT Genomics that Prenetics does not own - were granted put options which allow these remaining shareholders to put their remaining shares to Prenetics under certain conditions. The liabilities arising from such put option are recorded as liabilities for puttable financial instrument, and are valued at the present value of the exercise price of the put option.

      [3] Represents number of authorized and issued shares as follows:


      June 30,


      March 31,


      December 31,


      2023


      2023


      2022







      Number of authorized shares of $0.0001 each

      500,000,000


      500,000,000


      500,000,000







      Number of issued shares

      157,905,434


      158,820,280


      136,983,110

      [4] Includes equity-settled share-based payment expenses (excluding share-based payment on listing) from continuing operations as follows:


      For the six months ended


      June 30,


      June 30,


      2023


      2022


      $


      $




      (Restated)

      Selling and distribution expenses

      103,868


      31,424

      Research and development expenses

      1,360,896


      1,245,847

      Administrative and other operating expenses

      4,731,546


      16,489,378

      Total equity-settled share-based payment expenses (excluding share-based

        payment on listing)

      6,196,310


      17,766,649


      For the three months ended


      June 30,


      March 31,


      June 30,


      2023


      2023


      2022


      $


      $


      $




      (Restated)


      (Restated)

      Selling and distribution expenses

      58,613


      45,255


      23,745

      Research and development expenses

      874,389


      486,507


      708,511

      Administrative and other operating expenses

      2,340,502


      2,391,044


      9,511,007

      Total equity-settled share-based payment expenses

        (excluding share-based payment on listing)

      3,273,504


      2,922,806


      10,243,263

      [5] The acquisition of the net assets of Artisan Acquisition Corp. ("Artisan") on May 18, 2022 does not meet the definition of a business under IFRS and has therefore been accounted for as a share-based payment. The excess of fair value of Prenetics shares issued over the fair value of Artisan's identifiable net assets acquired represents compensation for the service of a stock exchange listing for its shares and is expensed as incurred.

      [6] We ceased our COVID-19 testing business entirely in 2023 Q2. As a result, COVID-19 testing business is reported as a discontinued operation under IFRS 5 Non-current Assets Held for Sale and Discontinued Operations. In accordance with IFRS 5, the results of the discontinued operation have been presented separately from the continuing operations in the consolidated statements of profit or loss and other comprehensive income. The comparative information in the consolidated statements of profit or loss and other comprehensive income has also been re-presented to show the results of discontinued operation separately.

      SOURCE Prenetics

      Modal title

      Contact PR Newswire

      • General Inquiries
      • Request a Demo
      • Partnerships
      • Media Inquiries

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Become a Publishing Partner
      • Careers
      • Accessibility Statement
      • APAC – Simplified Chinese
      • APAC
      • APAC - Traditional Chinese
      • Arabic
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • United States
      • Vietnam

      My Services

      • All New Releases
      • Platform

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Platform
      [email protected]
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      • Accessibility
      Copyright © 2026 Cision US Inc.